Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
INCY Stock Chart & Stats
$98.84
$0.53(0.72%)
At close: 4:00 PM EST
$98.84
$0.53(0.72%)
Day’s Range― - ―
52-Week Range$53.56 - $112.29
Previous CloseN/A
Volume384.35K
Average Volume (3M)1.87M
Market Cap
$19.67B
Enterprise Value$17.09B
Total Cash (Recent Filing)$3.58B
Total Debt (Recent Filing)$69.43M
Price to Earnings (P/E)15.4
Beta0.44
Next Earnings
May 05, 2026EPS Estimate
1.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.80
Shares Outstanding199,014,480
10 Day Avg. Volume1,853,385
30 Day Avg. Volume1,871,064
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.73
Price to Sales (P/S)3.75
P/FCF Ratio14.23
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue3.32
Enterprise Value/Gross Profit3.62
Enterprise Value/Ebitda9.71
Forecast
1Y Price Target
$109.13Price Target Upside10.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Anti‑mutant CALR And MCALR Clinical ProgressPromising early clinical proof‑of‑concept for the anti‑mutant CALR antibody and advancement toward pivotal trials for the mCALR program could de‑risk the pipeline and bolster expectations for future product launches.
Niktimvo Commercial PotentialStrong late-line performance for Niktimvo suggests a larger chronic graft‑versus‑host disease market opportunity, which could support meaningful revenue upside if adoption expands beyond current use.
Povorcitinib Market OpportunityPovorcitinib could serve as a valuable oral alternative in hidradenitis suppurativa and potentially capture patients who failed biologics, creating upside beyond current expectations for dermatology revenue.
Bears Say
Higher Operating Expenses And Limited CapitalRising operating expenses from research and product launches are reducing profitability and constraining capital available for business development, raising concerns about the company’s ability to fund growth initiatives.
Jakafi Revenue Replacement RiskPromising pipeline assets may be insufficient to fully replace revenue lost after Jakafi loses exclusivity, leaving the company dependent on successful late‑stage trial outcomes to sustain sales.
Opzelura Pricing And Competitive PressureNew pharmacy benefit manager agreements and intense competition in atopic dermatitis are creating net pricing pressure for Opzelura, which is likely to weigh on revenue growth.
Incyte News
INCY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was $53.56 and its highest was $112.29 in the past 12 months.
What is Incyte Corp’s market cap?
Incyte Corp’s market cap is $19.67B.
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is May 05, 2026 which is in 80 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Feb 10, 2026. The company reported $1.8 earnings per share for the quarter, missing the consensus estimate of $1.902 by -$0.102.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is 1.43.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 199,014,480 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $1.8 in its last earnings report, missing expectations of $1.902. Following the earnings report the stock price went down -8.236%.
Which hedge fund is a major shareholder of Incyte Corp?
Currently, no hedge funds are holding shares in INCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$109.13 (10.41% Upside)
$109.13 (10.41% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 90%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 983.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.01%
12-Months-Change
Fundamentals
Return on Equity
29.87%
Trailing 12-Months
Asset Growth
27.15%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
INCY Company Deck
INCY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a broadly positive commercial and pipeline narrative: strong 2025 revenue growth, robust core business expansion (ex-Jakafi), multiple high-impact late-stage programs, and constructive 2026 guidance. Offsetting risks include an Opsilora PN setback requiring another study, rising R&D spending to support numerous pivotal trials, pricing/formulary tradeoffs, and the need to successfully launch and gain approvals for several products to replace Jakafi over the coming years. Overall, the positives—notably broad-based revenue growth, accelerating non-Jakafi franchises, and deepened late-stage pipeline—outweigh the challenges and execution risks outlined.View all INCY earnings summariesINCY Revenue Breakdown
84.69% Product revenues, net
12.39% Product royalty revenues
2.92% Milestone and contract revenues
INCY Stock 12 Month Forecast
Average Price Target
$109.13
▲(10.41% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---